Bactiguard announces new number of shares and votes
The increase results from Class C shares issued for LTIP 2026, with 715,000 Class C shares repurchased.
See the latest news and media coverage for Bactiguard. We track all announcements, press releases, and industry mentions in real time, all in one place.
Medical technology company specializing in infection prevention
bactiguard.comLast updated
In short: Bactiguard reported revenue growth in Q2 2026 and announced that its founder, Christian Kinch, sold his entire stake to Thomas von Koch.
The increase results from Class C shares issued for LTIP 2026, with 715,000 Class C shares repurchased.
Total revenue increased 9% to SEK 57.1 million in Q2 2026, with net sales up 12%. EBITDA margin was 4.6%.
The 715,000 shares are for delivery under LTIP 2026 and will be converted to Class B shares.
No dividend was paid, board and auditor re-elected, new incentive program approved, and share repurchase authorized.
Bactiguard's founder and former CEO Christian Kinch is selling his entire holding to Tombact AB, which is controlled by the company's largest shareholder Thomas von Koch.
The medical technology company Bactiguard reports a net profit of minus 8.2 million kronor for the second quarter of 2026 (minus 8.1).
Solid performance driven by revenue growth Second quarter 2026 (April - June)Total revenue amounted to SEK 57.1 (52.1) million, an increase of SEK 4.9 million...
The medical technology company Bactiguard has decided on a directed new issue of redeemable and convertible C-shares and on a share buyback of shares in the C-series.
Track Bactiguard and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.
Browse news for competitors to Bactiguard and other trending companies.